The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV
antibody index and clinical data in patients treated with
natalizumab

J 2021

The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab

KOLČAVA, Jan, Monika HULOVÁ, Lucie ŘÍHOVÁ, Josef BEDNAŘÍK, Pavel ŠTOURAČ et. al.

Základní údaje

Originální název

The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab

Autoři

KOLČAVA, Jan (203 Česká republika, garant, domácí), Monika HULOVÁ (203 Česká republika, domácí), Lucie ŘÍHOVÁ (203 Česká republika), Josef BEDNAŘÍK (203 Česká republika, domácí) a Pavel ŠTOURAČ (203 Česká republika, domácí)

Vydání

NEUROLOGICAL SCIENCES, New York, Springer, 2021, 1590-1874

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30103 Neurosciences

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.830

Kód RIV

RIV/00216224:14110/21:00120838

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s10072-020-04897-2

UT WoS

000590250900003

Klíčová slova anglicky

Natalizumab; Multiple sclerosis; T lymphocytes; Flow cytometry; JC virus

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 2. 2022 13:40, Mgr. Tereza Miškechová

Anotace

V originále

Background Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern. Methods This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data-No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab. Results Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 +/- 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (- 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (- 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (- 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (- 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period exhibited a lower CD4/CD8 ratio (1.89 +/- 1.08 vs. 2.5 +/- 0.73; p < 0.04). Conclusion This contribution reports the CD4/CD8 ratio as a possible biomarker for better clinical efficacy of natalizumab in patients exhibiting a lower CD4/CD8 ratio. NIL did not correlate with long-term therapeutic efficacy in patients treated with natalizumab, but was demonstrated as lower in patients JCV-seroconverting in the course of follow-up.

Návaznosti

MUNI/A/1325/2019, interní kód MU

Název: Diagnostika a patofyziologie neuropatické bolesti (Akronym: PNB)

Investor: Masarykova univerzita, Diagnostika a patofyziologie neuropatické bolesti, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

MUNI/A/1600/2020, interní kód MU

Název: Diagnostika a patofyziologie neuropatické bolesti (Akronym: PNB)

Investor: Masarykova univerzita, Diagnostika a patofyziologie neuropatické bolesti

Citovat

KOLČAVA, Jan, Monika HULOVÁ, Lucie ŘÍHOVÁ, Josef BEDNAŘÍK a Pavel ŠTOURAČ. The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab. NEUROLOGICAL SCIENCES. New York: Springer, 2021, roč. 42, č. 7, s. 2847-2853. ISSN 1590-1874. Dostupné z: https://dx.doi.org/10.1007/s10072-020-04897-2.

@article{1703176,
   author = {Kolčava, Jan and Hulová, Monika and Říhová, Lucie and Bednařík, Josef and Štourač, Pavel},
   article_location = {New York},
   article_number = {7},
   doi = {http://dx.doi.org/10.1007/s10072-020-04897-2},
   keywords = {Natalizumab; Multiple sclerosis; T lymphocytes; Flow cytometry; JC virus},
   language = {eng},
   issn = {1590-1874},
   journal = {NEUROLOGICAL SCIENCES},
   title = {The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab},
   url = {https://link.springer.com/article/10.1007/s10072-020-04897-2},
   volume = {42},
   year = {2021}
}

TY  - JOUR
ID  - 1703176
AU  - Kolčava, Jan - Hulová, Monika - Říhová, Lucie - Bednařík, Josef - Štourač, Pavel
PY  - 2021
TI  - The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab
JF  - NEUROLOGICAL SCIENCES
VL  - 42
IS  - 7
SP  - 2847-2853
EP  - 2847-2853
PB  - Springer
SN  - 15901874
KW  - Natalizumab
KW  - Multiple sclerosis
KW  - T lymphocytes
KW  - Flow cytometry
KW  - JC virus
UR  - https://link.springer.com/article/10.1007/s10072-020-04897-2
L2  - https://link.springer.com/article/10.1007/s10072-020-04897-2
N2  - Background Natalizumab is an effective therapy in the treatment of relapsing-remitting multiple sclerosis; it induces lymphocytosis (NIL, natalizumab-induced lymphocytosis) and changes the peripheral lymphocyte pattern. Methods This study aims to evaluate NIL, peripheral blood lymphocyte subsets, CD4/CD8 ratio, and their impacts on JCV index and clinical data-No Evidence of Disease Activity (NEDA-3) and annualized relapse rate (ARR) in patients treated with natalizumab. Results Forty-one patients (33 women) were included in the study. The mean duration of follow-up on natalizumab treatment was 6.7 +/- 3.2 years. Significant increases in relative lymphocytosis after 1 month, with a median of 40.4% (- 34.1 to + 145.5%) (p < 0.001), and after 1 year (49.0% (- 9.3 to + 127.6%)) (p < 0.001) were found. Significant differences were found after 1 month when comparing NIL between patients JCV-seroconverting (20.6% (- 17.7 to 72.7%)) and stable JCV-seronegative ones (43.5% (- 6.3 to +96.3%)) (p = 0.04). No significant difference NIL level was found between the patients exhibiting NEDA-3 status and those without it. ARR on natalizumab treatment correlated with CD4/CD8 ratio (r = 0.356; p = 0.021); patients who maintained NEDA-3 status over the whole treatment period exhibited a lower CD4/CD8 ratio (1.89 +/- 1.08 vs. 2.5 +/- 0.73; p < 0.04). Conclusion This contribution reports the CD4/CD8 ratio as a possible biomarker for better clinical efficacy of natalizumab in patients exhibiting a lower CD4/CD8 ratio. NIL did not correlate with long-term therapeutic efficacy in patients treated with natalizumab, but was demonstrated as lower in patients JCV-seroconverting in the course of follow-up.
ER  -

KOLČAVA, Jan, Monika HULOVÁ, Lucie ŘÍHOVÁ, Josef BEDNAŘÍK a Pavel ŠTOURAČ. The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab. \textit{NEUROLOGICAL SCIENCES}. New York: Springer, 2021, roč.~42, č.~7, s.~2847-2853. ISSN~1590-1874. Dostupné z: https://dx.doi.org/10.1007/s10072-020-04897-2.

Podrobný výpis o publikaci